185 related articles for article (PubMed ID: 27918237)
1. GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer.
Pelosof L; Yerram S; Armstrong T; Chu N; Danilova L; Yanagisawa B; Hidalgo M; Azad N; Herman JG
Epigenetics; 2017 Jul; 12(7):540-550. PubMed ID: 27918237
[TBL] [Abstract][Full Text] [Related]
2. Methylation of TMEM176A is an independent prognostic marker and is involved in human colorectal cancer development.
Gao D; Han Y; Yang Y; Herman JG; Linghu E; Zhan Q; Fuks F; Lu ZJ; Guo M
Epigenetics; 2017 Jul; 12(7):575-583. PubMed ID: 28678648
[TBL] [Abstract][Full Text] [Related]
3. Methylation of SLFN11 is a marker of poor prognosis and cisplatin resistance in colorectal cancer.
He T; Zhang M; Zheng R; Zheng S; Linghu E; Herman JG; Guo M
Epigenomics; 2017 Jun; 9(6):849-862. PubMed ID: 28403629
[TBL] [Abstract][Full Text] [Related]
4. Correlation between the promoter methylation status of ATP-binding cassette sub-family G member 2 and drug sensitivity in colorectal cancer cell lines.
Moon HH; Kim SH; Ku JL
Oncol Rep; 2016 Jan; 35(1):298-306. PubMed ID: 26497773
[TBL] [Abstract][Full Text] [Related]
5. Frequent epigenetic suppression of tumor suppressor gene glutathione peroxidase 3 by promoter hypermethylation and its clinical implication in clear cell renal cell carcinoma.
Liu Q; Jin J; Ying J; Sun M; Cui Y; Zhang L; Xu B; Fan Y; Zhang Q
Int J Mol Sci; 2015 May; 16(5):10636-49. PubMed ID: 25970749
[TBL] [Abstract][Full Text] [Related]
6. The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer.
Lin X; Stenvang J; Rasmussen MH; Zhu S; Jensen NF; Tarpgaard LS; Yang G; Belling K; Andersen CL; Li J; Bolund L; Brünner N
BMC Genomics; 2015 May; 16(1):404. PubMed ID: 25997618
[TBL] [Abstract][Full Text] [Related]
7. Retinoic acid-induced 2 (RAI2) is a novel tumor suppressor, and promoter region methylation of RAI2 is a poor prognostic marker in colorectal cancer.
Yan W; Wu K; Herman JG; Xu X; Yang Y; Dai G; Guo M
Clin Epigenetics; 2018; 10():69. PubMed ID: 29796120
[TBL] [Abstract][Full Text] [Related]
8. KIF18b-dependent hypomethylation of PARPBP gene promoter enhances oxaliplatin resistance in colorectal cancer.
Hong B; Lu R; Lou W; Bao Y; Qiao L; Hu Y; Liu K; Chen J; Bao D; Ye M; Fang Z; Gong C; Zhang X
Exp Cell Res; 2021 Oct; 407(2):112827. PubMed ID: 34508743
[TBL] [Abstract][Full Text] [Related]
9. Silencing GPX3 Expression Promotes Tumor Metastasis in Human Thyroid Cancer.
Zhao H; Li J; Li X; Han C; Zhang Y; Zheng L; Guo M
Curr Protein Pept Sci; 2015; 16(4):316-21. PubMed ID: 25929866
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of glutathione peroxidase 1 (GPX1) down-regulation and correlation with aberrant promoter methylation in human gastric cancer.
Min SY; Kim HS; Jung EJ; Jung EJ; Jee CD; Kim WH
Anticancer Res; 2012 Aug; 32(8):3169-75. PubMed ID: 22843889
[TBL] [Abstract][Full Text] [Related]
11. CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.
Pelosof L; Yerram SR; Ahuja N; Delmas A; Danilova L; Herman JG; Azad NS
Int J Cancer; 2014 Feb; 134(3):596-605. PubMed ID: 23873170
[TBL] [Abstract][Full Text] [Related]
12. Methylation of
Zheng R; Gao D; He T; Zhang M; Zhang X; Linghu E; Wei L; Guo M
Clin Epigenetics; 2017; 9():50. PubMed ID: 28491151
[TBL] [Abstract][Full Text] [Related]
13. The role of hERG1 ion channels in epithelial-mesenchymal transition and the capacity of riluzole to reduce cisplatin resistance in colorectal cancer cells.
Fortunato A
Cell Oncol (Dordr); 2017 Aug; 40(4):367-378. PubMed ID: 28593575
[TBL] [Abstract][Full Text] [Related]
14. Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin.
Sharp SY; O'Neill CF; Rogers P; Boxall FE; Kelland LR
Eur J Cancer; 2002 Nov; 38(17):2309-15. PubMed ID: 12441268
[TBL] [Abstract][Full Text] [Related]
15. Identification of GPX3 epigenetically silenced by CpG methylation in human esophageal squamous cell carcinoma.
He Y; Wang Y; Li P; Zhu S; Wang J; Zhang S
Dig Dis Sci; 2011 Mar; 56(3):681-8. PubMed ID: 20725785
[TBL] [Abstract][Full Text] [Related]
16. Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines.
Virag P; Perde-Schrepler M; Fischer-Fodor E; Tatomir C; Dorneanu SA; Cernea VI; Irimie A
Anticancer Drugs; 2012 Nov; 23(10):1032-8. PubMed ID: 22614106
[TBL] [Abstract][Full Text] [Related]
17. Silencing of glutathione peroxidase 3 through DNA hypermethylation is associated with lymph node metastasis in gastric carcinomas.
Peng DF; Hu TL; Schneider BG; Chen Z; Xu ZK; El-Rifai W
PLoS One; 2012; 7(10):e46214. PubMed ID: 23071548
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells.
Lu WQ; Hu YY; Lin XP; Fan W
Oncotarget; 2017 Jul; 8(27):44171-44185. PubMed ID: 28498807
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic and Glucocorticoid Receptor-Mediated Regulation of Glutathione Peroxidase 3 in Lung Cancer Cells.
An BC; Jung NK; Park CY; Oh IJ; Choi YD; Park JI; Lee SW
Mol Cells; 2016 Aug; 39(8):631-8. PubMed ID: 27484907
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines.
Kitada N; Takara K; Minegaki T; Itoh C; Tsujimoto M; Sakaeda T; Yokoyama T
Cancer Chemother Pharmacol; 2008 Sep; 62(4):577-84. PubMed ID: 18030470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
